EGFR and non-small cell lung carcinoma: The IMpower150 trial demonstrated the efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) therapy in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC).